Meningococcal Group B Vaccine (2 dose)
{{DrugProjectFormSinglePage |authorTag=Martin Nino [1] |genericName=Meningococcal Group B Vaccine (2 dose) |aOrAn=a |drugClass=vaccine |indicationType=prevention |indication=invasive disease caused by ''Neisseria meningitidis'' serogroup B |adverseReactions=pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥ 28%), nausea (≥18%), and arthralgia (≥13%) |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content) |fdaLIADAdult=======Indications====== Meningococcal Group B Vaccine is indicated for active immunization to prevent invasive disease caused by ''Neisseria meningitidis'' serogroup B. Meningococcal Group B Vaccine is approved for use in individuals 10 through 25 years of age.
Approval of Meningococcal Group B Vaccine is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of Meningococcal Group B Vaccine against diverse serogroup B strains has not been confirmed.
Dosage
- For intramuscular use only.
- Administer two doses (0.5 mL each) of Meningococcal Group B Vaccine at least 1 month apart.
Use of Meningococcal Group B Vaccine with other Meningococcal Group B Vaccines Sufficient data are not available on the safety and effectiveness of using Meningococcal Group B Vaccine and other meningococcal group B vaccines interchangeably to complete the vaccination series. |offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Meningococcal Group B Vaccine (2 dose) in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Meningococcal Group B Vaccine (2 dose) in adult patients. |fdaLIADPed=Safety and effectiveness of Meningococcal Group B Vaccine have not been established in children younger than 10 years of age. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Meningococcal Group B Vaccine (2 dose) in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Meningococcal Group B Vaccine (2 dose) in pediatric patients. |administration=Shake the syringe immediately before use to form a homogeneous suspension. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is found.
Administer Meningococcal Group B Vaccine as a 0.5 mL intramuscular injection into the deltoid muscle of the upper arm.
|contraindications= Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of Meningococcal Group B Vaccine. |warnings=
Preventing and Managing Allergic Reactions
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.
Syncope=
Syncope (fainting) can occur in association with administration of Meningococcal Group B Vaccine. Ensure procedures are in place to avoid injury from falling associated with syncope.
Latex
The tip caps of the pre-filled syringes contain natural rubber latex which may cause allergic reactions in latex sensitive individuals.
Limitation of vaccine effectiveness
Meningococcal Group B Vaccine may not protect all vaccine recipients. Meningococcal Group B Vaccine may not provide protection against all meningococcal serogroup B strains.
Altered Immunocompetence
Individuals with altered immunocompetence may have reduced immune responses to Meningococcal Group B Vaccine. |clinicalTrials= The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%).
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
In four clinical trials, 3058 individuals 10 through 25 years of age received at least one dose of Meningococcal Group B Vaccine, 1436 participants received only Meningococcal Group B Vaccine, 2089 received only placebo or a control vaccine, and 1622 participants received a mixed regimen (placebo or control vaccine and Meningococcal Group B Vaccine).
In a randomized controlled study1 conducted in US and Poland, 120 participants 10 through 25 years of age received at least one dose of Meningococcal Group B Vaccine, including 112 participants who received 2 doses of Meningococcal Group B Vaccine 2 months apart; 97 participants received saline placebo followed by Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]. Across groups, median age was 13 years, males comprised 49% and 60% were White; 34% were Hispanic, 4% were Black,<1% were Asian, and 2% were other.
In a second randomized controlled study2 conducted in Chile, all subjects (N=1,622) 11 through 17 years of age received at least one dose of Meningococcal Group B Vaccine. This study included a subset of 810 subjects who received 2 doses of Meningococcal Group B Vaccine 1 or 2 months apart. A control group of 128 subjects received at least 1 dose of placebo containing aluminum hydroxide. A subgroup of 128 subjects received 2 doses of Meningococcal Group B Vaccine 6 months apart. In this study, median age was 14 years, males comprised 44%, and 99% were Hispanic.
In a third randomized controlled study3 conducted in the United Kingdom (UK), 974 university students 18 through 24 years of age received at least 1 dose of Meningococcal Group B Vaccine, including 932 subjects who received 2 doses of Meningococcal Group B Vaccine 1 month apart. Comparator groups received 1 dose of Menveo followed by 1 dose of placebo containing aluminum hydroxide (N=956) or 2 doses of IXIARO (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) (N=947). Across groups, median age was 20 years, males comprised 46%, and 88% were White, 5% were Asian, 2% were Black, <1% were Hispanic, and 4% were other.
In an uncontrolled study4 conducted in Canada and Australia, 342 participants 11 through 17 years of age received at least 1 dose of Meningococcal Group B Vaccine, including 338 participants who received 2 doses of Meningococcal Group B Vaccine 1 month apart. The median age was 13 years, males comprised 55%, and 80% were White, 10% were Asian, 4% were Native American/Alaskan, and 4% were other.
Local and systemic reactogenicity data were solicited from all participants in the studies conducted in Chile, US/Poland, Canada/Australia, and in a subset of participants in the UK study. Reports of unsolicited adverse events occurring within the first 7 days after each vaccination were collected in all studies. In the US/Poland study, reports of unsolicited adverse events were collected up to one month after the second vaccination.
Reports of all serious adverse events, medically attended adverse events and adverse events leading to premature withdrawal were collected throughout the study period for the studies conducted in Chile (12 months), UK (12 months), US/Poland (8 months), and Canada/Australia (2 months).
- Solicited Adverse Reactions
The reported rates of local and systemic reactions among participants 10 through 25 years of age following each dose of Meningococcal Group B Vaccine administered 2 months apart or control in the US/Polish study1 are presented in TABLE 1.
- Table 1: Percentage of US and Polish Participants 10 through 25 Years of Age Reporting Solicited Local and Systemic Adverse Reactions within 7 Days after Meningococcal Group B Vaccine or Control, by Dose
BEXSERO : Meningococcal Group B Vaccine's Brand name
Solicited adverse reaction rates were similar among participants 11 through 24 years of age who received Meningococcal Group B Vaccine in the other three clinical studies,2,3,4 except for severe myalgia which was reported by 3-7% of subjects. Severe pain was reported by 8% of university students in the UK3.
- Non-serious Adverse Events
In the 3 controlled studies1,2,3 (Meningococcal Group B Vaccine N=2221, control N=2204), non-serious unsolicited adverse events that occurred within 7 days of any dose were reported by 439 (20%) Meningococcal Group B Vaccine and 197 (9%) control recipients. Unsolicited adverse events that were reported among at least 2% of participants and were more frequently reported in Meningococcal Group B Vaccine recipients than in control recipients were injection site pain, headache, and injection site induration unresolved within 7 days, and nasopharyngitis.
- Serious Adverse Events
Overall, in clinical studies, among 3,058 participants 10 through 25 years of age who received at least 1 dose of Meningococcal Group B Vaccine, 66 (2.1%) participants reported serious adverse events at any time during the study. In the 3 controlled studies1,2,3 (Meningococcal Group B Vaccine N=2716, Control N=2078), serious adverse events within 30 days after any dose were reported in 23 (0.8%) Meningococcal Group B Vaccine recipients and 10 (0.5%) control recipients.
Additional Pre-licensure Safety Experience
In response to outbreaks of serogroup B meningococcal disease at two universities in the US, Meningococcal Group B Vaccine was administered as a 2 dose series at least 1 month apart. Information on serious adverse events was collected for a period of 30 days after each dose from 15,351 individuals 16 through 65 years of age who received at least 1 dose. Overall 50 individuals (0.3%) reported serious adverse events, including one event considered related to vaccination, a case of anaphylaxis within 30 minutes following vaccination.
|drugInteractions= |useInPregnancyFDA= |useInNursing= |useInPed= |useInGeri= |useInRenalImpair= |useInHepaticImpair= |administration= |overdose= |drugBox=
Meningococcal Group B Vaccine (2 dose)
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |